Objective: To calculate the incidence and prevalence of altitude illness (acute mountain sickness [AMS], high altitude pulmonary edema, and high altitude cerebral edema) during an expedition length adventure race and to determine factors contributing to its development as well as identify cases requiring medical treatment, withdrawal from the event, or both.
Methods: The Primal Quest Expedition Length Adventure Race was held in Colorado in July 2002. Sixty-two coed teams of four participated in the event. It began at an altitude of over 9500 feet, ascended to an altitude over 13,500 feet with a cumulative elevation gain of 69,400 feet, of which 40,000 feet occurred in the first 12 hours of the event. There was 138,800 total feet of altitude change during the event. All racers underwent a prerace medical assessment 24 hours before the start of the race and completed an Environmental Systems Questionnaire version 3-R (ESQ 3-R). Onsite medical staff provided treatment during the event. A standard medical encounter form was used to record all patient encounters including a presumed diagnosis and disposition.
Results: At the start of the race, the prevalence of altitude illness was 4.5%. The incidence of altitude illness requiring medical treatment during the race was 14.1% (AMS, 33 [13.3%]; high altitude pulmonary edema, 2 [.81%]) resulting in 4 (14.3%) of the 28 medical withdrawals from the race. There was no correlation between home altitude, prerace ESQ scores, and successful completion of the race.
Conclusions: Altitude illness occurs among participants in expedition length adventure races and contributes significantly to withdrawal from the event.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1580/1080-6032(2004)015[0090:taihai]2.0.co;2 | DOI Listing |
Open Access J Sports Med
December 2024
Department of Exercise Physiology, College of Sport Sciences and Physical Activity, King Saud University, Riyadh, Saudi Arabia.
Background: Un-acclimatized individuals may experience acute altitude illness. Thus, the current study investigated the impact of short-term intermittent normobaric hypoxia (NH) combined with light exercise on the acclimatization of cardiorespiratory function to altitude in inactive adults.
Methods: This quasi-experimental study recruited 10 inactive university students (age: 26.
Nat Rev Dis Primers
December 2024
Altitude Research Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Int J Ophthalmol
December 2024
Shaanxi Eye Hospital, Xi'an People's Hospital (Xi'an Fourth Hospital), Affiliated People's Hospital of Northwest University, Xi'an 710004, Shaanxi Province, China.
Aim: To quantify the severity and frequency of ocular pain in Tibetan plateau patients with dry eye, and to evaluate the related factors affecting ocular pain.
Methods: A retrospective study included 160 cases of dry eye disease (DED) patients who were treated from July 2022 to June 2023. Age, gender, occupation, illness course, anxiety, plateau duration, plateau protection, ocular surface disease index scale (OSDI), break-up time (BUT), Schirmer I test (SIT), conjunctivitis, history of ophthalmic medication, autoimmune disease, the workload of daily near vision range, smoking and overnight stay were obtained comprehensive ophthalmic assessment, and their duration was followed up.
Discov Oncol
December 2024
Department of Pharmacology, College of Medicine, Taif University, P.O. Box 11099, Taif 21944, Taif, Saudi Arabia.
Breast cancer remains one of the most challenging diseases to treat due to its heterogeneity, propensity to recur, capacity to spread to distant vital organs, and, ultimately, patient death. Estrogen receptor-positive illness comprises the most common breast cancer subtype. Preclinical progress is hampered by the scarcity of medication-naïve estrogen receptor-positive tumour models that recapitulate metastatic development and treatment resistance.
View Article and Find Full Text PDFWilderness Environ Med
December 2024
Department of Emergency Medicine, University of Vermont, Burlington, VT.
Introduction—: Mount Aconcagua (6961 m) in Argentina is the highest peak in the Americas, and more than 3000 climbers attempt to summit annually. High altitude pulmonary edema (HAPE) is a leading cause of mortality and evacuation on Aconcagua.
Objective—: This study sought to describe the characteristics of climbers who developed HAPE on Aconcagua to aid in future prevention efforts.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!